Novel Analgesic Drug Holds New Promise For Chronic Pain Relief

Novel Analgesic Drug Holds New Promise For Chronic Pain Relief
Musculoskeletal conditions are the most common cause of chronic pain and affect roughly one in five adults in Europe, according to a new paper published in Reumatismo -- the official journal of the Italian Society of Rheumatology. The paper, entitled "Chronic pain: the burden of disease — and treatment innovations," (Reumatismo. 2015 Oct 23;67(2):35-44. DOI: http://dx.doi.org/10.4081/reumatismo.2015.840), is coauthored by S. Monti and R. Caporali of the Unità Operativa Complessa di Reumatologia at the Università di Pavia's IRCCS Fondazione S. Matteo, in Pavia, Italy, who note that persistent chronic pain becomes disease itself, with associated substantial clinical, social and economic impact. The coauthors observe that efficacy and tolerability problems are characteristic of all therapeutic strategies available for treating musculoskeletal pain -- a reality that often limits effective analgesia and patients' long term treatment compliance, with the result that chronic pain is persistently underestimated and under-treated. Drs. Monti and Caporali report that Tapentadol, a novel, centrally acting analgesic recently commercialized for treatment of chronic pain, holds new promise for relief. Sold under the trade name NUCYNTA ER, Tapentadol is a centrally acting opioid analgesic of the benzenoid class with a dual mode of action that is indicated for management of pain severe enough to require daily, round-the-clock, long-term opioid treatment and for which alternative treatment optio
Subscribe or to access all post and page content.